High intensity focused ultrasound (HIFU) for prostate cancer: Current clinical status, outcomes and future perspectives

International Journal of Hyperthermia

Volumn 26, Issue 8, 2010, Pages 796-803

  Crouzet, Sebastien ^a   Murat, Francois J ^b   Pasticier, Gilles ^c   Cassier, Philippe ^a   Chapelon, Jean Y ^d,e   Gelet, Albert ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Clinique Val d'Ouest   (France)

^c HÔPITAL PELLEGRIN   (France)

^d INSERM   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

High intensity focused ultrasound, localised prostate cancer, predition and monitoring of tumour response, thermal ablation, ultrasound surgery

Indexed keywords

DOCETAXEL;

ALOPECIA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FUTUROLOGY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MORBIDITY; POSTOPERATIVE PERIOD; PRIMARY MEDICAL CARE; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; RETREATMENT; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION;

DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 78149260570     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2010.498803     Document Type: Review

References (55)

1. Yancik R. Population aging and cancer: A cross-national concern. Cancer J 2005;11:437-441.
2. Ferlay J, Parkin DM. Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
3. Lynn JG, Zwemer RL, Chick AJ, Miller AE. A new method for the generation and use of focused ultrasound in experimental biology. J Gen Physiol 1942;26:179-193.
4. Lynn JG, Putnam TJ. Histology of cerebral lesions produced by focused ultrasound. Am J Pathol 1944;20:637-649.
5. Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Cathignol D, Blanc E. Prostatic tissue destruction by high-intensity focused ultrasound: Experimentation on canine prostate. J Endourol 1993;7:249-253. (Pubitemid 23223859)
6. Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R, Bouvier R. High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol 1993;23:S44-47.
7. Madersbacher S, Kratzik C, Szabo N, Susani M, Vingers L, Marberger M. Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol 1993;23:S39-43.
8. Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van de Kaa CA, Debruyne FM, de la Rosette JJ. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: Results of a prospective study. Prostate 1999;39:41-46.
9. Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: Surgery of the future? Br J Radiol 2003;76:590-599.
10. Rouvière O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, Dubernard JM, Gelet A. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001;40:265-274.
11. de Senneville BD, Mougenot C, Moonen CT. Real-time adaptive methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn Reson Med 2007;57:319-330.
12. Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martignoni G, Artibani W. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 2006;98:1193-1198.
13. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006;97:56-61.
14. Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: Feasibility study. J Urol 2004;171:2265-2267.
15. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006;24:585-590.
16. Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006;9:439-443.
17. Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-387.
18. Rebillard X, Davin JL, Soulie M. [Treatment by HIFU of prostate cancer: survey of literature and treatment indications]. Prog Urol 2003;13:1428-1456.
19. Associazione Urologi Italiani (AURO) The Association of Italian Urologist (TAoUI). Guidelines, Prostate Cancer. 2009;2:76-77.
20. Uchida T, Nakano M, Shoji S, Omaat N, Harano H, Nagata Y, Usui Y, Terachi T. Ten year biochemical disease free survival after high intensity focused ultrasound (HIFU) for localised prostate cancer: Comparison with three different generation devices. J Urol 2009;181:228.
21. Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M. High-intensity-focused ultrasound in the treatment of primary prostate cancer: The first UK series. Br J Cancer 2009;101:19-26.
22. Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Rebillard X, Rewcastle JC, Robertson CN, et al. Primary prostate HIFU without pretreatment hormone therapy: Biochemical survival of 468 patients tracked with the-registry. J Urol 2009;181:227.
23. Mearini L, D'Urso L, Collura D, Zucchi A, Costantini E, Formiconi A, Bini V, Muto G, Porena M. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 2009;181:105-112.
24. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008;53:1194-1201.
25. Misrai V, Rouprêt M, Chartier-Kastler E, Comperat E, Renard-Penna R, Haertig A, Bitker MO, Richard F, Conort P. Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol 2008 Oct;26:481-485.
26. Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, Walter B. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008;72:1329-1334.
27. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 2008;53:57-53.
28. Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T, Satoh T. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006;13:228-233.
29. Thuroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, Desgrandchamps F, De La Rosette JJ, Gelet A. High-intensity focused ultrasound and localized prostate cancer: Efficacy results from the European multicentric study. J Endourol 2003;17:673-677. (Pubitemid 37362918)
30. Chaussy C, Thuroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 2001;15:437-440; discussion 447-448. (Pubitemid 32467092)
31. Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lasne Y, Lyonnet D, Dubernard JM. Transrectal high-intensity focused ultrasound: Minimally invasive therapy of localized prostate cancer. J Endourol 2000;14:519-528.
32. Challacombe BJ, Murphy DG, Zakri R, Cahill DJ. High-intensity focused ultrasound for localized prostate cancer: Initial experience with a 2-year follow-up. BJU Int 2009;104:200-204.
33. Maestroni U, Ziveri M, Azzolini N, Dinale F, Ziglioli F, Campaniello G, Frattini A, Ferretti S. High Intensity Focused Ultrasound (HIFU): A useful alternative choice in prostate cancer treatment. Preliminary results. Acta Biomed 2008;79:211-216.
34. Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, Sanghvi NT. Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol 2007;178:2366-2371.
35. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocar-cinoma of the prostate? BJU Int 2006;98:537-539.
36. Crouzet S, Murat FJ, Rouviere O, Poissonnier L, Martin X, Colombel M, Chapelon JY, Gelet A. Outcomes of HIFU for prostate cancer in 880 consecutive patients. J Urol 2010;183:759.
37. Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World J Urol 2003;21:200-208. (Pubitemid 44177416)
38. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010;28:1106-1111.
39. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74.
40. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330-337.
41. Borghede G, Aldenborg F, Wurzinger E, Johansson KA, Hedelin H. Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy. Br J Urol 1997;80:247-255.
42. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355-367.
43. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002;54:677-685.
44. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-881. (Pubitemid 32750970)
45. Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008;179:1368-1373.
46. Zapatero A, Minguez R, Nieto S, Martin de Vidales C, Garcia-Vicente F. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: What can they teach us? Eur Urol 2009;55:902-909.
47. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radio-recurrent prostate cancer. Eur Urol 2009;55:640-647.
48. Pasticier G, Riviere J, Wallerand H, Robert G, Bernhard JC, Ferriere JM, et al. Salvage radiotherapy (SRT) for local recurrence of prostate adenocarcinoma after primary treatment with high intensity focused ultrasound (HIFU): First series of 100 patients. Paper presented at the 2010 ASCO Annual Meeting, June 4-8, Chicago, IL, USA.
49. Ahmed HU, Sahu M, Govindaraju SK, Arumainayagam N, Scott R, Illing RO, et al. High intensity focused ultrasound (HIFU) hemiablation trial in localised unilateral prostate cancer: Interim results. Eur Urol Supp 2009;8:334.
50. Villers A, Lemaitre L, Haffner J, Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: Implications for focal therapy and active surveillance. Curr Opin Urol 2009;19:274-282.
51. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology 2009;74:1094-1099.
52. Puech P, Betrouni N, Makni N, Dewalle AS, Villers A, Lemaitre L. Computer-assisted diagnosis of prostate cancer using DCE-MRI data: Design, implementation and preliminary results. Int J Comput Assist Radiol Surg 2009;4:1-10.
53. Lecornet E, Ahmed HU, Moore CM, Emberton M. Conceptual basis for focal therapy in prostate cancer. J Endourol 2010;24:811-818.
54. Paparel P, Curiel L, Chesnais S, Ecochard R, Chapelon JY, Gelet A. Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005;95:881-885.
55. Paparel P, Chapelon JY, Bissery A, Chesnais S, Curiel L, Gelet A. Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: Results of a preliminary study. Prostate Cancer Prostatic Dis 2008;11:181-186.